Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Net Income (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Net Income for 10 consecutive years, with -$6.0 million as the latest value for Q4 2025.

  • Quarterly Net Income changed N/A to -$6.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$26.3 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$26.3 million for FY2025, N/A changed from the prior year.
  • Net Income hit -$6.0 million in Q4 2025 for Aptevo Therapeutics, up from -$7.6 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $946000.0 in Q1 2023 to a low of -$7.6 million in Q3 2025.
  • Historically, Net Income has averaged -$1.7 million across 4 years, with a median of $157000.0 in 2022.
  • Biggest five-year swings in Net Income: tumbled 96.79% in 2021 and later surged 431.46% in 2023.
  • Year by year, Net Income stood at $325000.0 in 2021, then surged by 60.31% to $521000.0 in 2022, then plummeted by 43.76% to $293000.0 in 2023, then tumbled by 2146.42% to -$6.0 million in 2025.
  • Business Quant data shows Net Income for APVO at -$6.0 million in Q4 2025, -$7.6 million in Q3 2025, and -$6.2 million in Q2 2025.